Biogen Inc. (BIIB)

225.85
NASDAQ : Health Technology
Prev Close 232.06
Day Low/High 225.10 / 231.87
52 Wk Low/High 216.12 / 358.41
Avg Volume 1.42M
Exchange NASDAQ
Shares Outstanding 184.45M
Market Cap 42.80B
EPS 21.60
P/E Ratio 8.65
Div & Yield N.A. (N.A)

Latest News

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

-- Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events --

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

— Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events — — Discontinuations Due to GI Events were Less than 1% for Diroximel Fumarate — DUBLIN,...

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

Release Your 'Inner Spock' When Investing in Biotech Stocks

Release Your 'Inner Spock' When Investing in Biotech Stocks

Be zen and keep emotions out of investing decisions. It can pay off in higher portfolio returns.

Biogen Rises on Strong Second-Quarter Earnings, Guidance Boost

Biogen Rises on Strong Second-Quarter Earnings, Guidance Boost

The drugmaker reports second-quarter results that beat analysts' forecasts and raises its guidance for the remainder of the year on strong demand for its multiple sclerosis and other disease-fighting medications.

Apple, Coca-Cola, Snap, Facebook, Debt Ceiling - 5 Things You Must Know

Apple, Coca-Cola, Snap, Facebook, Debt Ceiling - 5 Things You Must Know

U.S. stock futures rise ahead of earnings reports from a number of corporate heavyweights and after the White House and congressional negotiators reach a budget deal that will lift the government's debt limit; Coca-Cola, Snap, Visa and Harley-Davidson are among the companies reporting earnings on Tuesday; Apple reportedly is in talks to buy Intel's modem chip business for $1 billion.

One Prescription for Uncertain Market? Gilead Sciences

One Prescription for Uncertain Market? Gilead Sciences

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

Will Gilead Sciences Stock Really Rally 33% From Here?

Will Gilead Sciences Stock Really Rally 33% From Here?

Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) As A Foundation Of Care In Spinal Muscular Atrophy For A Broad Range Of Patients

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) As A Foundation Of Care In Spinal Muscular Atrophy For A Broad Range Of Patients

- New results from the NURTURE study demonstrate that pre-symptomatic infants treated with SPINRAZA are achieving motor milestones that are unprecedented in the natural history of the disease, including 100 percent of children sitting without support and 88 percent walking independently

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

The firm now has a neutral rating on Biogen based on data from a new neurologist survey.

Biogen Could Rally in the Weeks Ahead

Biogen Could Rally in the Weeks Ahead

Buyers have returned in recent months and the stock could be ready to rise.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Getting Nervous

After days of complacency, we see a shift in sentiment and folks are getting the jitters.

Time to Get Back to What I Do Best: Shorting Stocks

Time to Get Back to What I Do Best: Shorting Stocks

After a five-year hiatus I'm ready to start throwing whammies in several directions.

Wedbush Securities Senior Vice President Of Equity Research Laura Chico, Ph.D. Initiates Coverage On Six Stocks In The Healthcare And BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA And SAGE

Wedbush Securities Senior Vice President Of Equity Research Laura Chico, Ph.D. Initiates Coverage On Six Stocks In The Healthcare And BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA And SAGE

LOS ANGELES, May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico, Ph.

Ups and Downs on the Way

Expect a bout of volatility next week as we straddle between oversold and overbought.

Rally? What Rally?

Tuesday's rise disappointed, but any downside from here should bring on negative sentiment while we’re oversold, which should give us a real rally.

Real Money Post-Industrial Average Leaves Major Indices in the Dust

Real Money Post-Industrial Average Leaves Major Indices in the Dust

RMPIA outperformed once gain during April.

Breakthrough Tuesday

New highs grow on the New York Stock Exchange and the Investor Intelligence bulls finally tops 55%.

Feels Like Deja Tuesday

Friday felt a lot like Tuesday -- in that it didn’t change any of the big indicators -- but we should still pay close attention to the Citigroup Panic/Euphoria Index, which is now kissing the underside of Euphoria.

Cramer's Takeaways for Ford, Chevron, Alibaba, Biogen, Visa

Cramer's Takeaways for Ford, Chevron, Alibaba, Biogen, Visa

What are the main takeaways from Chevron, Ford and others? Cramer explains.

Jim Cramer Responds to Elon Musk, Talks Intel, Chevron, Ford and More

Jim Cramer Responds to Elon Musk, Talks Intel, Chevron, Ford and More

Need a road map to close out this week on Wall Street? Jim Cramer breaks down everything investors need to know about the markets from Chevron to Intel.

Jim Cramer Responds to Elon Musk, Talks Intel, Chevron, Ford and More

Jim Cramer Responds to Elon Musk, Talks Intel, Chevron, Ford and More

Need a road map to close out this week on Wall Street? Jim Cramer breaks down everything investors need to know about the markets from Chevron to Intel.

TheStreet Quant Rating: C (Hold)